• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Review links PTSD to metabolic dysfunction, proposes drug repurposing

by
November 16, 2026
in Health
Reading Time: 7 mins read
0
Review links PTSD to metabolic dysfunction, proposes drug repurposing

Review links PTSD to metabolic dysfunction, proposes drug repurposing

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A comprehensive narrative review published in Frontiers in Behavioral Neuroscience examines the growing body of evidence linking post-traumatic stress disorder (PTSD) to systemic metabolic dysfunction. The study, led by Iryna Halabitska and colleagues, argues that PTSD is not merely a disorder of fear memory but a whole-body condition closely associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. The authors propose that these comorbidities share convergent biological mechanisms, including dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, neuroinflammation, and mitochondrial dysfunction. By identifying these shared nodes, the review suggests a rationale for repurposing approved cardiometabolic drugs as potential treatments for PTSD, a strategy currently described as promising but unproven.

The review highlights that current pharmacological options for PTSD are limited, with only two selective serotonin reuptake inhibitors, sertraline and paroxetine, officially approved. These medications often yield modest effect sizes, and many patients do not achieve remission. Furthermore, some off-label treatments can exacerbate metabolic issues by causing weight gain or elevating blood glucose levels. The authors argue that the overlap between PTSD and metabolic disease represents a missed opportunity in clinical practice. By leveraging the known safety profiles and pharmacokinetics of existing metabolic drugs, researchers could potentially develop faster and less risky therapeutic strategies for trauma-affected populations.

Central to the review’s argument is the concept of biological convergence between PTSD and metabolic disorders. The authors identify four key shared nodes: the HPA axis and glucocorticoid receptor signaling, chronic low-grade inflammation and glial activation, central and peripheral insulin resistance, and mitochondrial bioenergetic failure. In PTSD, altered cortisol feedback and higher glucocorticoid receptor sensitivity are linked to inflammation and poor fear extinction. Similarly, in metabolic disease, hypercortisolism drives visceral fat accumulation and insulin resistance. The review emphasizes that while these associations are well-documented in human studies, the direction of causality remains uncertain, with peripheral abnormalities potentially acting as consequences rather than primary causes of central psychopathology.

One of the most discussed candidate drug classes in the review is glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide. Originally developed for type 2 diabetes and obesity, these drugs are increasingly studied for their neuroprotective effects. GLP-1 receptors are widely expressed in brain regions involved in emotional regulation, including the hippocampus and amygdala. Preclinical studies using the single-prolonged-stress model have shown that long-term administration of liraglutide can reduce anxiety-like behavior and decrease neuronal activation in stress-responsive brain regions. However, the authors note that no randomized clinical trials have yet evaluated these drugs specifically in patients with PTSD, and human genetic evidence regarding their causal protective effects remains inconsistent.

Other candidate therapeutics evaluated in the review include insulin sensitizers like metformin and PPAR-γ agonists such as pioglitazone. Metformin activates AMPK and blocks the NLRP3 inflammasome, potentially stabilizing mitochondria and lowering oxidative stress. While the mechanistic rationale is strong, direct clinical evidence for its use in PTSD is currently lacking. Pioglitazone has shown neuroprotective effects in models of traumatic brain injury and Parkinson’s disease, and it has been used in controlled neuropsychiatric trials in veterans, though not specifically for PTSD. The review also considers statins, SGLT2 inhibitors, and renin-angiotensin system modulators, noting that their evidence levels vary significantly, with most resting on observational or preclinical data rather than dedicated randomized controlled trials.

The strongest clinical evidence among the repurposed candidates comes from angiotensin type 1 receptor (AT1R) blockers, specifically losartan. A randomized, placebo-controlled trial involving 149 patients with PTSD tested losartan’s ability to improve fear extinction and modify memory reconsolidation. While the trial demonstrated the feasibility of testing a cardiometabolic drug in a PTSD population, it did not show clear superiority over placebo on the primary PTSD outcome. This result underscores the difficulty of translating mechanistic plausibility into clinical efficacy. The review grades the evidence for losartan as Level 1, indicating the presence of a dedicated randomized trial, but clarifies that this does not imply that therapeutic efficacy has been definitively established.

To address the heterogeneity of PTSD, the authors propose a biomarker-guided framework for precision psychiatry. Rather than treating all patients with the same drug, this approach suggests matching therapies to the dominant biological mechanism of the individual. For instance, a patient with clear insulin resistance or obesity might be prioritized for trials of incretin-based therapies, while a patient with an inflammatory phenotype could be considered for glial-immune modulators. This stratification aims to increase the probability of detecting treatment effects by enriching study populations with patients who have the specific biological targets the drugs are designed to address. The framework acknowledges that biomarkers currently serve as research tools rather than validated clinical algorithms for treatment selection.

The review also discusses the unique context of war-affected Ukraine as a priority setting for future mechanism-based clinical trials. The conflict has created one of the largest mental-health crises in Europe since the Second World War, with elevated PTSD risk documented in nearly one-third of displaced Ukrainians. The convergence of psychological trauma and cardiometabolic disease in this population, exacerbated by disrupted healthcare access and chronic stress, provides a real-world context for evaluating integrated trauma and metabolic care. Because many candidate agents are inexpensive and widely available, they may be particularly suitable for pragmatic clinical trials in resource-constrained humanitarian settings.

Significant limitations remain in the field of metabolic drug repurposing for PTSD. The authors caution that preclinical animal models do not reproduce the full complexity of the human PTSD syndrome, often modeling only specific components like fear extinction or stress responses. Additionally, the direction of the relationship between central and peripheral abnormalities is not fully resolved, making it difficult to determine whether peripheral metabolic improvements will translate into direct neuropsychiatric benefits. Safety considerations are also critical, as these drugs can have adverse effects such as gastrointestinal issues, weight changes, or blood pressure fluctuations, which must be carefully monitored in patients with multiple comorbidities.

In conclusion, the review positions metabolic drug repurposing as a hypothesis-generating strategy rather than an established therapeutic approach. The next priority for the field is to determine which peripheral abnormalities are mechanistically linked to PTSD neurobiology and whether central or peripheral target engagement is required for therapeutic effects. By moving beyond diagnosis-based enrollment toward biomarker-guided stratification, researchers may be able to identify biologically distinct PTSD subtypes and match them with appropriate interventions. This precision-psychiatry framework offers a complementary strategy to existing treatments, expanding the therapeutic repertoire using established medicines while addressing the systemic nature of the disorder.

The review distinguishes between the presence of a clinical trial and the demonstration of therapeutic benefit, a nuance critical for interpreting the current evidence base. While losartan is the only candidate drug to reach the highest evidence level due to a dedicated randomized controlled trial in PTSD, the authors explicitly state that this designation does not confirm efficacy. The trial’s failure to show clear superiority over placebo on primary outcomes serves as a cautionary example of how mechanistic plausibility does not automatically translate into clinical success. This distinction is applied across all other drug classes, where evidence levels range from human observational data to purely mechanistic reasoning. The authors emphasize that for most candidates, including GLP-1 receptor agonists and statins, the available data remain indirect or preclinical, requiring prospective testing to establish any direct effect on PTSD symptoms.

Translational validity remains a significant hurdle, particularly regarding the use of animal models. The review notes that no current preclinical paradigm reproduces the complete human PTSD syndrome, which is a multidimensional clinical disorder. Instead, models such as single prolonged stress or predator exposure assess selected behavioral and physiological proxies, such as impaired fear extinction or altered HPA-axis activity. These readouts are not specific to PTSD and often overlap with depression or anxiety-like phenotypes. Consequently, preclinical findings are treated as hypothesis-generating rather than definitive. The authors propose a staged translational pathway that requires replication across multiple models, inclusion of both sexes, and demonstration of target engagement in humans before larger efficacy trials are pursued.

Safety and pharmacokinetic considerations further complicate the repurposing strategy. The review highlights that adverse effects vary by drug class and must be interpreted within the context of the target population, which often includes patients with multiple psychiatric and cardiometabolic comorbidities. For instance, GLP-1 receptor agonists carry signals regarding mood changes and suicidal behavior, while pioglitazone is associated with weight gain and fluid retention. Statins may cause myopathy, and AT1R blockers can lower blood pressure, limiting their use in hypotensive patients. Additionally, the review cautions against generalizing findings from one compound to an entire pharmacological class, as drugs within the same class may differ substantially in blood-brain barrier penetration, receptor affinity, and off-target effects. For example, preclinical data for liraglutide cannot automatically establish equivalent central nervous system effects for semaglutide.

The review also addresses the challenge of distinguishing direct neuropsychiatric effects from indirect improvements in general health. Weight loss, better glycemic control, and reduced systemic inflammation may improve psychological well-being without necessarily modifying the specific pathophysiology of PTSD. To address this, the authors recommend that future trials prespecify PTSD-specific clinical outcomes using validated symptom scales, independent of metabolic endpoints. Mediation analyses should be used to determine whether changes in metabolic variables account for changes in PTSD symptoms. This approach ensures that any observed benefits are not solely attributed to the improvement of comorbid metabolic conditions, which, while clinically valuable, do not prove a direct action on trauma-related neural circuits.

Finally, the review underscores the importance of rigorous safety monitoring and the need for pragmatic trial designs suitable for real-world settings. Patients with PTSD frequently present with complex medical histories, including renal dysfunction and polypharmacy, which increases the risk of drug interactions and adverse events. The authors suggest that future studies should include predefined stopping criteria and subgroup analyses for high-risk populations. By integrating these safety and methodological considerations, the field can move toward a more precise and effective approach to treating the metabolic and psychiatric dimensions of PTSD.

Subject of Research: Review of metabolic mechanisms in PTSD and potential drug repurposing strategies

Article Title: Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics

Article References: Halabitska, I., Petakh, P., Kamyshna, I., Lushchak, O., & Kamyshnyi, O. (2026). Metabolic reprogramming in PTSD: GLP-1 receptor agonists and cardiometabolic drug repurposing for precision therapeutics. Frontiers in Behavioral Neuroscience, 20, Article 1957516. https://doi.org/10.3389/fnbeh.2026.1957516

Image Credits: AI Generated

DOI: 10.3389/fnbeh.2026.1957516

Keywords: PTSD, metabolic dysfunction, drug repurposing, GLP-1 receptor agonists, precision psychiatry, neuroinflammation, insulin resistance, cardiometabolic disease, Ukraine, clinical trials, Metabolic, reprogramming

News Source: Ophelia Keating. (November 16, 2026). Review links PTSD to metabolic dysfunction, proposes drug repurposing. Scienmag.

Tags: cardiometabolic diseaseClinical TrialsDrug repurposingGLP-1 receptor agonistsinsulin resistancemetabolicmetabolic dysfunctionNeuroinflammationprecision psychiatryPTSDreprogrammingUkraine
Share12Tweet7Share2ShareShareShare1

Related Posts

Targeted Psoriasis Biologics Reshape Immune-Adipose Crosstalk and Suppress Inflammatory Visfatin

Targeted Psoriasis Biologics Reshape Immune-Adipose Crosstalk and Suppress Inflammatory Visfatin

November 17, 2026
Wastewater Genomics Detects SARS-CoV-2 Mutations Months Before Clinical Identification

Wastewater Genomics Detects SARS-CoV-2 Mutations Months Before Clinical Identification

November 17, 2026

Cell Morphomics Reveals Shared Structural Pathology Across Diverse Neurological Diseases in Human Models

November 17, 2026

Geospatial Study Shows Thirty Million Ethiopians Face Two-Hour Walk to Healthcare

November 17, 2026

POPULAR NEWS

  • Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    Orthognathic Mixed Reality Templates Show Sub-Two-Millimeter Deviations in Early Scoping Review

    29 shares
    Share 12 Tweet 7
  • Iron Oxide Nanoparticles Alleviate Cadmium Stress and Accumulation in Atractylodes Lancea

    29 shares
    Share 12 Tweet 7
  • Elevated Lipoprotein (a) Does Not Predict Long-Term Mortality After Heart Attack

    29 shares
    Share 12 Tweet 7
  • Incremental Deep Learning Reconstruction Improves High-Resolution Coronary CT Angiography Image Quality

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Extracellular Matrix Mechanical Remodeling Drives Pathological Feedback Across Diverse Chronic Diseases

Targeted Psoriasis Biologics Reshape Immune-Adipose Crosstalk and Suppress Inflammatory Visfatin

Wastewater Genomics Detects SARS-CoV-2 Mutations Months Before Clinical Identification

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.